10:07 AM EST - DRI Healthcare Trust : DRI Healthcare Trust (TSX: DHT.UN) today commented on Viridian Therapeutics, Inc.'s recently announced approval by the U.S. Food and Drug Administration of Lumvoa™ (veligrotug-vvze) for the treatment of thyroid eye disease. TED is an autoimmune inflammatory disorder of the orbit (eye socket) that affects numerous patients in the U.S. and can cause debilitating and disfiguring eye symptoms (e.g., inflammation, proptosis, and double-vision) with severe disease leading to vision loss. DRI Healthcare Trust
shares T.DHT.UN are trading up $0.66 at $18.11.
